NCT01220518View on ClinicalTrials.gov

Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)

PHASE1CompletedINTERVENTIONAL

Enrollment

257

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

June 30, 2012

Conditions

Ankylosing Spondylitis

Interventions

DRUG

Infliximab

Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.

Trial Locations (1)

Unknown

Inha University Hostpital, Incheon

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celltrion

INDUSTRY